Methodological considerations in calculation of the trough: peak ratio

Area of Science:

• Pharmacology
• Clinical Trial Design
• Cardiovascular Medicine

Background:

• The U.S. Food and Drug Administration (FDA) has established guidelines for satisfactory antihypertensive drug efficacy based on trough: peak ratios.
• Current FDA guidelines lack specific methodologies, leading to inconsistent published data and unreliable trough: peak ratio calculations.
• Accurate trough: peak ratio determination is crucial for assessing antihypertensive drug efficacy and appropriate dosing intervals.

Purpose of the Study:

• To define essential methodological requirements for accurately and reproducibly measuring trough and peak antihypertensive effects.
• To establish a standardized approach for calculating the trough: peak ratio for antihypertensive medications.
• To address inconsistencies in published data stemming from methodological variations.

Main Methods:

• Addressing the impact of placebo effects on antihypertensive drug efficacy measurements.
• Accounting for circadian variability in blood pressure to accurately interpret peak effects.
• Proposing a sequential, placebo-active treatment design as a practical alternative to crossover designs, despite inherent difficulties.

Main Results:

• The study outlines critical factors for accurate trough: peak ratio calculation, including placebo effect and circadian blood pressure variations.
• It highlights the limitations of existing methodologies and the need for standardized approaches.
• The proposed methodology aims to improve the reliability of trough: peak ratio assessments.

Conclusions:

• A minimum 4-week placebo run-in period is recommended for accurate trough: peak ratio calculation.
• Standardized patient conditions and multiple blood pressure recordings throughout the dosing interval are essential.
• A sequential, placebo-active treatment design can yield acceptable accuracy and reproducibility for trough: peak ratio determination.